share_log

Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

Aadiバイオサイエンスは2024年第3四半期の業績と企業情報を報告します

PR Newswire ·  10/30 16:05

LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

About Aadi Bioscience

Aadi is a precision oncology company focused on the commercialization of FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at and connect with us on Twitter and LinkedIn.

Contact:
[email protected]

SOURCE Aadi Bioscience

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする